Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response
Introduction
Neoadjuvant chemotherapy has become the standard of care for patients with locally advanced breast cancer and has rapidly come to the forefront among potential treatments for patients with earlier-stage operable disease 1, 2. Several clinical trials have compared preoperative and postoperative chemotherapy in operable breast cancer, but no significant advantage in terms of long-term survival has been demonstrated to date 3, 4, 5, 6, 7, 8, 9.The only demonstrated benefit in terms of treatment effects of neoadjuvant chemotherapy in operable breast cancer is the achievement of tumour shrinkage, which allows more conservative treatment in some patients [10]. The response of breast tumours to preoperative chemotherapy might also be predictive of the efficacy of therapy on distant micrometastatic disease and outcome. A possible advantage of primary systemic treatment is to test the in vivo tumour response in order to modify treatment or introduce new drugs postoperatively. However, the response of the primary breast tumour to preoperative chemotherapy could simply be associated with better prognostic factors. The standard predictive and prognostic factors established in primary breast cancer may not carry the same value in breast cancer patients initially treated with chemotherapy rather than surgery. The independent prognostic value of tumour response, distinct from that of other prognostic factors such as tumour size, tumour grade and hormone sensitivity, should be demonstrated.
Since 1981, at the Institut Curie, neoadjuvant chemotherapy has also been used in large operable breast cancers, prior to local regional treatment. The aim of this study was to retrospectively assess the prognostic value of clinical response after preoperative chemotherapy in breast cancers prospectively registered in the database of one institution.
Section snippets
Patients
The present study was a retrospective analysis of the Institut Curie Breast Cancer database. This database was initiated in 1981 to prospectively register data for all patients treated for breast cancer at the Institut Curie [11]. The selection criteria were prior neoadjuvant chemotherapy for operable T2 or T3, N0 or N1 tumours. Patients with metastatic, locally advanced or inflammatory cancer were excluded, as were patients with bilateral tumours, prior cancer and male patients. Between 1981
Results
Pretreatment patient and tumour characteristics are summarised in Table 1. Median age was 47 years. Seventy-five percent of patients were premenopausal. Median tumour size was 4.5 cm (range: 2–12 cm). Sixty-five percent of the patients had clinical lymph node involvement. The pathological and laboratory characteristics of the tumours were as follows: 82% of tumours were grade II or III, 85% of tumours were ductal carcinomas, progesterone receptors (PR) were positive in 54% of patients and
Discussion
As response to preoperative chemotherapy is correlated with survival, response could be used as an intermediate endpoint to determine the value of new chemotherapy regimens or new drugs administered after well-established regimens [17]. Since this intermediate endpoint can be achieved within weeks after starting preoperative chemotherapy, new regimens or new active agents could be evaluated promptly and useful conclusions could be drawn without a 5- to 10-year waiting period, as is currently
Acknowledgements
We would like to acknowledge the Breast Cancer Group of the Institut Curie.
References (42)
- et al.
Primary chemotherapy for early and advanced breast cancer
Cancer Lett.
(1995) - et al.
Neoadjuvant chemotherapy in women with invasive breast carcinomaconceptual basis and fundamental surgical issues
J. Am. Coll. Surg.
(2000) - et al.
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgerypreliminary results of a randomised trial: S6
Eur. J. Cancer
(1994) - et al.
Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
Ann. Oncol.
(1994) - et al.
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cma unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS)
Ann. Oncol.
(1999) - et al.
Preoperative (neoadjuvant) chemotherapy in patients with breast cancer
Semin. Oncol.
(2001) - et al.
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival
Eur. J. Cancer
(1995) A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer
Eur. J. Cancer
(2001)- et al.
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
J. Clin. Oncol.
(1995) - et al.
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
J. Clin. Oncol.
(1998)
Preoperative chemotherapy in primary operable breast cancerresults from the European Organization for Research and Treatment of Cancer trial 10902
J. Clin. Oncol.
Short and long-term effects on survival in breast cancer patients treated by primary chemotherapyan updated analysis of a randomized trial
Breast Cancer Res. Treat.
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancerfindings from National Surgical Adjuvant Breast and Bowel Project B-18
J. Clin. Oncol.
Primary chemotherapy for operable breast cancerincidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery
J. Clin. Oncol.
Randomised trial of neoadjuvant chemotherapy in operable breast cancer comparing Adriamycin-Cyclophosphamide (CPM)- 5FU (ACF) versus Thiotepa- CPM- 5FU (TCF)
Ann. Oncol.
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
Br. J. Cancer
Nonparametric estimation from incomplete observations
J. Am. Stat. Assoc.
Evaluation of survival data and two new rank order statistics arising in its consideration
Cancer Chemother. Rep.
Regression models and life tables
J. Stat. Soc. B
Preoperative chemotherapya model for studying the biology and therapy of primary breast cancer
J. Clin. Oncol.
[Tumor regression as a prognostic factor in breast cancer]
Bull. Cancer
Cited by (76)
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage
2017, BreastCitation Excerpt :Lack of reaching a pathological complete response after neoadjuvant chemotherapy is a well established factor associated with higher risk of recurrence and death, especially in triple negative or HER2-positive breast cancer [11]. Absence of downstaging after neoadjuvant chemotherapy has been also reported as a strong predictive factor of poor outcome [12–14]. A residual bulky lymph nodal status is indicative of a biologically aggressive tumor resistant to neoadjuvant treatment and is negatively associated with survival [15,16].
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage ii or iii her2-negative breast cancer
2014, Clinical Breast CancerCitation Excerpt :Neoadjuvant chemotherapy (NCT) provides an opportunity to assess clinical, image-guided, and pathologic tumor response.1-4 Several neoadjuvant trials have shown that a pathologic complete response (pCR) correlates well with favorable long-term outcomes and may be a surrogate marker for survival.5-7 Whereas anthracycline-based regimens were extensively evaluated in the neoadjuvant setting, there is need to evaluate non–anthracycline-containing NCT regimens.
Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer
2013, Clinical Breast Cancer